Detalles de la búsqueda
1.
Patient preferences for chronic lymphocytic leukemia treatments: a discrete-choice experiment.
Future Oncol;
: 1-12, 2024 May 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38861284
2.
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Haematologica;
107(1): 134-142, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33327712
3.
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Future Oncol;
18(33): 3689-3699, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36102212
4.
Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA.
J Comp Eff Res;
13(2): e230119, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38294335
5.
COVID-19 Vaccination Response and Its Practical Application in Patients With Chronic Lymphocytic Leukemia.
Hemasphere;
7(1): e811, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36570695
6.
Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.
Leuk Lymphoma;
63(12): 2765-2784, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35983732
7.
A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies.
EJHaem;
3(2): 492-506, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35846043
8.
Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial.
Lancet Haematol;
8(12): e879-e890, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34826411
9.
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Blood Adv;
6(15): 4553-4557, 2022 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35736670
10.
Obinutuzumabe no tratamento de pacientes com leucemia linfoide crônica, não elegíveis à dose completa de fludarabina: análise de impacto orçamentário baseado no tempo para a próxima terapia / Obinutuzumab for the treatment of unfit patients with chronic lymphocytic leukemia: budget impact analysis based on time to next treatment
J. bras. econ. saúde (Impr.);
9(1): http://www.jbes.com.br/images/v9n1/2.pdf, Abril, 2017.
Artículo
en Portugués
| LILACS, ECOS | ID: biblio-833553
11.
Análise de custo-efetividade de obinutuzumabe associado à quimioterapia para o tratamento de pacientes adultos com leucemia linfoide crônica não elegíveis ao tratamento baseado em fludarabina na perspectiva do Sistema Único de Saúde (SUS) / Cost-effectiveness analysis of obinutuzumab associated to chemotherapy for the treatment of chronic lymphocytic leukemia patients ineligible for fludarabine under the Brazilian Public Healthcare System (SUS)
J. bras. econ. saúde (Impr.);
9(Suplemento 1): http://www.jbes.com.br/images/v9ns1/41.pdf, Setembro/2017.
Artículo
en Portugués
| ECOS, LILACS | ID: biblio-859499
12.
Ressecçöes hepáticas para metástases de câncer colorretal: um procedimento seguro e eficaz / Hepatic resection for metastases colorectal cancer: a safe and effective procedure
Rev. cient. AMECS;
9(2): 19-25, jul.-dez. 2000. ilus, tab
Artículo
en Portugués
| LILACS | ID: lil-281030
Resultados
1 -
12
de 12
1
Próxima >
>>